{
  "chapter": "Monoclonal Antibodies",
  "questions": [
    {
      "q_no": 1,
      "question": "Question 1: Cetuximab is approved for use in which of the following conditions?",
      "options": {
        "a": "Palliation in head and neck cancer",
        "b": "Anal canal carcinoma",
        "c": "Gastric carcinoma",
        "d": "Lung carcinoma"
      },
      "correct_answer": "a",
      "explanation": "Cetuximab is used for palliation in head and neck cancer. Indications for use of cetuximab are: • Advanced squamous cell carcinoma of the head and neck in combination with radiotherapy for \nlocally or regionally • Metastatic colorectal cancer Cetuximab is a recombinant chimeric monoclonal antibody against the external domain of the \nepidermal growth factor receptor (EGFR).",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Monoclonal Antibodies"
    },
    {
      "q_no": 2,
      "question": "Question 2: A patient diagnosed with metastatic colorectal carcinoma is being treated with panitumumab. \nThis drug acts against which of the following receptors?",
      "options": {
        "a": "PDGFR",
        "b": "EGFR",
        "c": "HER2/neu receptor",
        "d": "VEGF receptor"
      },
      "correct_answer": "b",
      "explanation": "Panitumumab is a recombinant fully-humanized monoclonal antibody that binds specifically to \nthe external domain of the epidermal growth factor receptor (EGFR). It is approved for use in patients with metastatic colorectal carcinoma.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Monoclonal Antibodies"
    },
    {
      "q_no": 3,
      "question": "Question 3: A 57-year-old woman is diagnosed with HER 2/neu positive breast cancer. Which of the \nfollowing monoclonal antibodies is indicated for the management of this patient?",
      "options": {
        "a": "Panitumumab",
        "b": "Cetuximab",
        "c": "Trastuzumab",
        "d": "Bevacizumab"
      },
      "correct_answer": "c",
      "explanation": "Trastuzumab is indicated for adjuvant therapy in early and metastatic HER2 positive breast \ncancer. Trastuzumab is a humanized monoclonal antibody that binds to the extracellular domain of \nHER2/Neu. Human epidermal growth factor receptor 2 tyrosine kinase receptor (HER-2-TK) inhibitors are: 878 \nSold by @itachibot • Lapatinib • Neratinib Anti-Her-2 monoclonal antibodies are: • Trastuzumab • Pertuzumab",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Monoclonal Antibodies"
    },
    {
      "q_no": 4,
      "question": "Question 4: A 57-year-old woman diagnosed with breast carcinoma was prescribed trastuzumab. Which of \nthe following statements regarding this drug is true?",
      "options": {
        "a": "It is an antibody produced entirely from mouse containing no human component",
        "b": "It is a monoclonal antibody produced by injecting HER-2 antigen",
        "c": "It is a polyclonal antibody",
        "d": "It is a monoclonal antibody containing only human component"
      },
      "correct_answer": "b",
      "explanation": "Trastuzumab is a humanized monoclonal antibody against the external domain of HER2/neu. In \nhumanized antibodies, all components are identical to human antibodies (95% human \ncomponent), except the complementary region of the variable chain that contains sequences from \nother species. It is indicated in the management of adjuvant therapy in early and metastatic HER-2 positive \nbreast cancer. Human epidermal growth factor receptor 2 tyrosine kinase receptor (HER-2-TK) inhibitors are: • Lapatinib • Neratinib Anti-Her-2 monoclonal antibodies are: • Trastuzumab • Pertuzumab",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Monoclonal Antibodies"
    },
    {
      "q_no": 5,
      "question": "Question 5: A patient was diagnosed with HER2/neu positive breast cancer and was started on adjuvant \ntherapy with trastuzumab. Which of the following is the most serious and dose-limiting \ntoxicity of this drug?",
      "options": {
        "a": "Nephrotoxicity",
        "b": "Neurotoxicity",
        "c": "Cardiotoxicity",
        "d": "Ototoxicity"
      },
      "correct_answer": "c",
      "explanation": "The most serious toxicity of trastuzumab is cardiac failure. Cardiac failure is a potentially \ndisabling or fatal side effect unless recognized early and the drug is discontinued. Cardiotoxicity is caused by the interruption of HER2/4 heterodimer signaling in cardiomyocytes, \nwhich is a type of signaling that is essential for the maintenance of contractile function. Clinical correlation: • Baseline ECG and cardiac ejection fraction should be monitored to rule out underlying heart \ndisease • Careful clinical follow-up for signs and symptoms of CHF Other side effects include fever, chills, nausea, dyspnea, and rashes. Dose-limiting toxicities are side effects of a drug or other treatment that are serious enough to \nprevent an increase in dose or level of that treatment. 879 \nSold by @itachibot",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Monoclonal Antibodies"
    },
    {
      "q_no": 6,
      "question": "Question 6: A patient diagnosed with wet age-related macular degeneration is being administered \nranibizumab intravitreally. All of the following are known side effects of the drug, except \n \n.",
      "options": {
        "a": "Eye pain",
        "b": "Fall in IOP",
        "c": "Conjunctival hemorrhage",
        "d": "Floaters"
      },
      "correct_answer": "b",
      "explanation": "Ranibizumab is associated with a raise in IOP, not a fall. Ranibizumab is a monoclonal antibody directed against VEGF-A (vascular endothelial growth \nfactor-A). Ranibizumab is indicated in wet age-related macular degeneration and is used \nintravitreally where it inhibits VEGF-A induced ocular neovascularization.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Monoclonal Antibodies"
    },
    {
      "q_no": 7,
      "question": "Question 7: Which among the following is the monoclonal antibody that is targeted specifically against \nVEGFR?",
      "options": {
        "a": "Bevacizumab",
        "b": "Ranibizumab",
        "c": "Ramucirumab",
        "d": "Aflibercept"
      },
      "correct_answer": "c",
      "explanation": "Ramucirumab is a monoclonal antibody that binds to VEGFR-2 and inhibits the binding of \nVEGFR ligands. It is indicated in NSCLC, gastric cancer and metastatic colorectal cancer. Bevacizumab, aflibercept and ranibizumab are monoclonal antibodies against VEGF ligands and \nnot the receptor.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Monoclonal Antibodies"
    },
    {
      "q_no": 8,
      "question": "Question 8: 872 \nSold by @itachibot Rituximab is not used in which of the following conditions?",
      "options": {
        "a": "Non-Hodgkin lymphoma",
        "b": "Paroxysmal nocturnal hemoglobinuria",
        "c": "Rheumatoid arthritis",
        "d": "Systemic lupus ertythematosis"
      },
      "correct_answer": "b",
      "explanation": "Rituximab is used in all conditions, except paroxysmal nocturnal hemoglobinuria. Indications for rituximab include: (mnemonic- CANT MIS Ritu): • CLL • Autoimmune hemolytic anemia • Non-Hodgkin lymphoma • TTP • Marginal zone lymphomas, mantle cell lymphoma, myasthenia gravis • ITP 880 \nSold by @itachibot • SLE • Rheumatoid arthritis It is a chimeric monoclonal antibody targeted against the CD20 receptor that is present on the \nsurface of B lymphocytes. Ofatumumab and obinutuzumab are the other monoclonal antibodies directed against CD20 \nreceptors. They are also approved for use in CLL.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Monoclonal Antibodies"
    },
    {
      "q_no": 9,
      "question": "Question 9: A 70-year-old man is found to have leukocytosis on his yearly health check-up. Further \nevaluation led to a diagnosis of chronic lymphocytic leukemia. Immunophenotyping was \npositive for CD52. Which is the monoclonal antibody indicated in this condition?",
      "options": {
        "a": "Rituximab",
        "b": "Alemtuzumab",
        "c": "Cetuximab",
        "d": "Obinutuzumab"
      },
      "correct_answer": "b",
      "explanation": "Alemtuzumab is a humanized monoclonal antibody against CD52 that is indicated in the \nmanagement of chronic lymphocytic leukemia (CLL). Rituximab and obinutuzumab are monoclonal antibodies against CD20 that are also indicated in \nthe treatment of chronic lymphocytic leukemia. Cetuximab is a chimeric human-mouse anti-epidermal growth factor receptor monoclonal \nantibody against the extracellular domain of EGFR.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Monoclonal Antibodies"
    },
    {
      "q_no": 10,
      "question": "Question 10: Which of the following monoclonal antibodies is not a HER1 inhibitor?",
      "options": {
        "a": "Pertuzumab",
        "b": "Cetuximab",
        "c": "Necitumumab",
        "d": "Panitumumab"
      },
      "correct_answer": "a",
      "explanation": "Pertuzumab is a monoclonal antibody against the HER2 receptor. Pertuzumab is indicated in HER2-positive breast cancer in combination with trastuzumab and \ndocetaxel. Monoclonal antibodies against EGFR (HER1) are: • Panitumumab • Cetuximab • Necitumumab",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Monoclonal Antibodies"
    },
    {
      "q_no": 11,
      "question": "Question 11: Which of the following is a monoclonal antibody directed against PDGFR-alpha?",
      "options": {
        "a": "Panitumumab",
        "b": "Pertuzumab",
        "c": "Cetuximab",
        "d": "Olaratumab"
      },
      "correct_answer": "d",
      "explanation": "Olaratumab is a monoclonal antibody against PDGFR-alpha and blocks ligand-mediated receptor \nactivation. It is indicated along with doxorubicin for adult patients with soft tissue sarcoma. Panitumumab and cetuximab are monoclonal antibodies against EGFR (HER1). Pertuzumab is a monoclonal antibody against HER2.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Monoclonal Antibodies"
    },
    {
      "q_no": 12,
      "question": "Question 12: 873 \nSold by @itachibot Which of the following is a bispecific monoclonal antibody?",
      "options": {
        "a": "Daratumumab",
        "b": "Alemtuzumab",
        "c": "Blinatumomab",
        "d": "Panitumumab"
      },
      "correct_answer": "c",
      "explanation": "Blinatumomab is a bispecific monoclonal antibody. 881 \nSold by @itachibot Bispecific monoclonal antibody simultaneously binds to two different types of antigen. It binds \nsimultaneously to CD3 on T cells and to CD19 on B cells. This links the two cells and activates T \ncells to exert cytotoxic activity against CD19 B cells. Blinatumomab is approved for the treatment of Philadelphia chromosome-negative relapsed or \nrefractory B-cell precursor ALL. Option A: Daratumumab is a monoclonal antibody against CD-3š. Option B: Alemtuzumab is a monoclonal antibody against CD-52. Option D: Panitumumab is a monoclonal antibody against EGFR.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Monoclonal Antibodies"
    },
    {
      "q_no": 13,
      "question": "Question 13: A 40-year-old man who presented with fever, night sweats and weight loss was evaluated and \ndiagnosed with diffuse large B-cell lymphoma. Which of the following is a \nradioimmunoconjugate that can be used in this condition?",
      "options": {
        "a": "Gemtuzumab ozogamicin",
        "b": "Brentuximab vedotin",
        "c": "Denileukin deftitox",
        "d": "Ibritumomab tiuxetan"
      },
      "correct_answer": "d",
      "explanation": "Ibritumomab tiuxetan is a radioimmunoconjugate that is approved for use in non-Hodgkin's \nlymphoma. Diffuse large B-cell lymphoma is a subtype of non-Hodgkin's lymphoma. Ibritumomab is a monoclonal antibody against CD20 which is attached to the radioactive isotope \nyttrium-90 using the chelator tiuxetan. Beta emission from Y-90 destroys the surrounding \ntissues. Radioimmunoconjugates provide targeted delivery of radionuclides to tumor cells. It is made by \nattaching a radioactive molecule to a monoclonal antibody. Option A: Gemtuzumab ozogamicin is a monoclonal antibody against CD33 covalently linked to a \nsemisynthetic derivative of calicheamicin which is a potent antitumor antibiotic. Option B: Brentuximab vedotin is a monoclonal antibody against CD30 linked with microtubule \ndisrupting agent MMAE. Option C: Denileukin diftitox is an immunotoxin produced by genetic recombination of IL-2 and \nthe catalytically active fragment of diphtheria toxin.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Monoclonal Antibodies"
    },
    {
      "q_no": 14,
      "question": "Question 14: What is basiliximab?",
      "options": {
        "a": "IL-1 receptor antagonist",
        "b": "Anti-CD3 antibody",
        "c": "IL-2 receptor antagonist",
        "d": "TNF inhibitor"
      },
      "correct_answer": "c",
      "explanation": "Basiliximab exhibits a high affinity towards IL-2 receptor and inhibits it. It is an anti- CD-25 \nmonoclonal antibody. It has a short plasma half-life of 1 week. It is used to prevent transplant rejection reactions. Its \nadverse effects are anaphylactic reactions &amp; opportunistic infections.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Monoclonal Antibodies"
    },
    {
      "q_no": 15,
      "question": "Question 15: A 2-year-old girl was brought to the hospital by her mother with complaints of abdominal \npain and diarrhea. Examination revealed a palpable abdominal mass. Investigations showed \nelevated levels of urinary homovanillic acid and vanillyl mandelic acid. The lesion could not \nbe completely resected during surgery and histopathology findings are shown in the image. \nWhich of the following is a monoclonal antibody approved for use in this condition? 874 \nSold by @itachibot",
      "options": {
        "a": "Alirocumab",
        "b": "Alemtuzumab",
        "c": "Dinutuximab",
        "d": "Denosumab"
      },
      "correct_answer": "c",
      "explanation": "The given scenario and the histopathology (image) showing small round blue tumor cells with \nHomer-Wright pseudorosettes, point towards a diagnosis of paediatric neuroblastoma. \nDinutuximab is the monoclonal antibody against glycolipid GD2 which is indicated in this \ncondition. 882 \nSold by @itachibot GD2 glycolipid is expressed on neuroblastoma cells and on normal cells of neuroectodermal \norigin, including the central nervous system and peripheral nerves.",
      "image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/mxpharmacology/Monoclonal_Antibodies_Q15_q.jpg",
      "explanation_image": null,
      "chapter_heading": "Monoclonal Antibodies"
    },
    {
      "q_no": 16,
      "question": "Question 16: Which of the following drugs is recently approved for the treatment of colorectal cancer \narising through Lynch Syndrome?",
      "options": {
        "a": "Ipilimumab",
        "b": "Nivolumab",
        "c": "Pembrolizumab",
        "d": "Atezolimumab"
      },
      "correct_answer": "c",
      "explanation": "Pembrolizumab is the drug recently approved for the treatment of colorectal cancer arising \nthrough Lynch syndrome. The increased risk for colorectal cancer in Lynch Syndrome is due to \ninherited mutations that impair DNA mismatch repair. Immune checkpoint inhibitors inhibit proteins that help to keep immune responses to cancer cells \nin check. When these proteins are blocked, the brake on the immune system is released and T \ncells are able to kill cancer cells more efficiently. Pembrolizumab is an immune checkpoint inhibitor. It is a humanized monoclonal IgG4- isotype \nantibody that blocks the interaction between programmed cell death protein (PD-1) and its \nligands. The FDA has approved pembrolizumab for patients with recurrent, locally advanced or metastatic, \nsquamous cell carcinoma of the esophagus and head and neck squamous cell cancer in \ncombination with platin agents and 5-FU for the first-line treatment.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Monoclonal Antibodies"
    },
    {
      "q_no": 17,
      "question": "Question 17: Pembrolizumab is not approved for use in which of the following malignancies?",
      "options": {
        "a": "Non-metastatic small cell lung cancer",
        "b": "Metastatic squamous cell lung cancer",
        "c": "Refractory classical hodgkin’s lymphoma",
        "d": "Urothelial cancer"
      },
      "correct_answer": "a",
      "explanation": "Pembrolizumab is not approved for use in non-metastatic small-cell lung cancer. It is approved for \nmetastatic small cell lung cancer (SCLC). Pembrolizumab is a monoclonal antibody (IgG4) against PD-1 and blocks interaction between \nPD-1 and its ligands PD-L1 and PD-L2. It is used in the following conditions: • Metastatic SCLC • Hodgkin’s lymphoma 883 \nSold by @itachibot • Metastatic urothelial cancer • Metastatic non SCLC • Merkel cell carcinoma • Chemotherapy-refractory head and neck cancers • Refractory melanoma • Triple-Negative Breast Cancer • Esophageal Cancer • Colorectal cancer due to Lynch syndrome",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Monoclonal Antibodies"
    },
    {
      "q_no": 18,
      "question": "Question 18: Which among the following is the Interleukin-5 antagonist indicated in the management of \nasthma?",
      "options": {
        "a": "Omalizumab",
        "b": "Lebrikizumab",
        "c": "Reslizumab",
        "d": "Atezolimumab"
      },
      "correct_answer": "c",
      "explanation": "Reslizumab is a monoclonal antibody against interleukin-5 that is approved for use in \nsevere asthma. Option A &amp; B: Omalizumab is an anti-IgE antibody and lebrikizumab is an antibody against \ninterleukin 13, which are also indicated in the management of asthma. Option D: Atezolizumab is an immune checkpoint modulator that inhibits the interaction of PD-L1 \nwith PD-1 and B7-H1. It is approved for use in metastatic urothelial cancer and for NSCLC.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Monoclonal Antibodies"
    },
    {
      "q_no": 19,
      "question": "Question 19: Which of the following is the monoclonal antibody developed against Bacillus anthracis?",
      "options": {
        "a": "Alemtuzumab",
        "b": "Omalizumab",
        "c": "Obiltoxaximab",
        "d": "Abciximab"
      },
      "correct_answer": "c",
      "explanation": "Obiltoxaximab is a monoclonal antibody against the protective antigen of Bacillus anthracis. It is indicated in the treatment of inhalational anthrax due to B. anthracis in combination with \nappropriate antibacterial drugs. It is also indicated for prophylaxis of inhalational anthrax.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Monoclonal Antibodies"
    },
    {
      "q_no": 20,
      "question": "Question 20: Which of the following is an immune checkpoint inhibitor?",
      "options": {
        "a": "Alemtuzumab",
        "b": "Denosumab",
        "c": "Durvalumab",
        "d": "Abciximab"
      },
      "correct_answer": "c",
      "explanation": "Durvalumab is an immune checkpoint inhibitor. It is an antagonist of PD-L1 which is a \nprotein-ligand that is present on antigen-presenting cells, T cells, B cells, and some cancer cells. Immune checkpoint inhibitors inhibit proteins that help the cancer cells evade the immune \nresponse. When these proteins are blocked, the brake on the immune system is released and T \ncells are able to kill cancer cells more efficiently. Durvalumab is approved for use in metastatic urothelial and Merkel cell cancer. The FDA \napproved Durvalumab in combination with etoposide and either carboplatin or cisplatin as \nfirst-line treatment of patients with extensive-stage small-cell lung cancer. Other PD-L1 inhibitors include: • Atezolizumab 884 \nSold by @itachibot • Avelumab • Durvalumab",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Monoclonal Antibodies"
    },
    {
      "q_no": 21,
      "question": "Question 21: A patient with rheumatoid arthritis has inadequate disease control with methotrexate. Which \nJanus kinase inhibitor can you add to his treatment regimen?",
      "options": {
        "a": "Ruxolitinib",
        "b": "Baricitinib",
        "c": "Dasatinib",
        "d": "Ponatinib"
      },
      "correct_answer": "b",
      "explanation": "Baricitinib is a Janus kinase inhibitor approved for use in rheumatoid arthritis. Oral Janus kinase inhibitors for rheumatoid arthritis are: • Baricitinib • Tofacitinib Option A: Ruxolitinib is a Janus kinase inhibitor approved for use in various forms of \nmyelofibrosis, polycythemia vera and acute graft vs host disease. Options C and D: Dasatinib and ponatinib are BCR-ABL tyrosine kinase inhibitors indicated for \nCML.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Monoclonal Antibodies"
    },
    {
      "q_no": 22,
      "question": "Question 22: A patient has presented to the OPD with raised erythematous plaques on his arms and torso \ncovered in silvery scales. You decide to prescribe a monoclonal antibody targeting \ninterleukin-23 for treatment. Identify this drug.",
      "options": {
        "a": "Secukinumab",
        "b": "Ixekizumab",
        "c": "Brodalumab",
        "d": "Tildrakizumab"
      },
      "correct_answer": "d",
      "explanation": "The scenario described in the question points towards a diagnosis of chronic plaque psoriasis. \nTildrakizumab is a monoclonal antibody directed against IL-23 used in the treatment of this \ncondition. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. \nTildrakizumab prevents the interaction of IL-23 with its receptors. It is indicated in \nmoderate-to-severe plaque psoriasis. Secukinumab, ixekizumab, brodalumab are other monoclonal antibodies directed against IL-17A \nand indicated in moderate-to-severe plaque psoriasis. Note: Ustekinumab is a monoclonal antibody against both IL-12 and IL-23. It is used for the \ntreatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Monoclonal Antibodies"
    },
    {
      "q_no": 23,
      "question": "Question 23: Dupilumab is indicated in the management of  \n.",
      "options": {
        "a": "Imatinib",
        "b": "Bevacizumab",
        "c": "Denosumab",
        "d": "Rituximab"
      },
      "correct_answer": "b",
      "explanation": "Dupilumab is indicated in the treatment of moderate-to-severe atopic dermatitis. Dupilumab inhibits interleukins IL-4 and IL-13. When these interleukins are inhibited, they are \nunable to form complexes with their receptors. This results in a decrease in the immune \nresponse including the release of proinflammatory cytokines, chemokines, and IgE. 885 \nSold by @itachibot Interleukins, Growth Factors and Targeted Therapies",
      "image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/mxpharmacology/Monoclonal_Antibodies_Q23_q.jpg",
      "explanation_image": null,
      "chapter_heading": "Monoclonal Antibodies"
    }
  ]
}
